Replies to post #5326 on EOM Pharmaceutical Holdings Inc. (IMUC)

[Renee]

Thanks, good to know. I own shares because of the zero debt and $3.5 million in cash, plus their intellectual property and research portfolio.

A public acquirer could easily benefit from ImmunoCellular Therapeutics prior reporting compliance, ie., all Financials and Filings were current up to the date the company deregistered, and a private acquirer could file a FORM 10 to register their amalgamated companies with the SEC, benefitting from ImmunoCellular Therapeutics SEC compliance before the company deregistered.

Very low risk with this stock, as I see it.

All Financials and Filings up to Nov. 6,2018:

https://www.sec.gov/cgi-bin/browse-edgar?company=ImmunoCellular+Therapeutics&owner=exclude&action=getcompany